Ionizable and cationic lipids

The development of ionizable and cationic lipids with diverse configurations addresses issues of low intracellular delivery and thermostability, enhancing therapeutic efficacy and global distribution of RNA formulations.

WO2026241487A1PCT designated stage Publication Date: 2026-11-19UNIVERSITY OF ALABAMA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028135
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing ionizable and cationic lipids for nucleic acid delivery face challenges such as low intracellular delivery, poor thermostability, limited biodegradability, and laborious synthesis processes, limiting therapeutic efficacy and global formulation distribution.

Method used

Development of ionizable and cationic lipids with diverse symmetric and asymmetric configurations, offering improved intracellular delivery, enhanced thermostability, and scalable manufacturing processes.

Benefits of technology

The new lipids achieve higher intracellular delivery efficiency and improved thermostability, facilitating broader therapeutic applications and global distribution of RNA formulations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028135_19112026_PF_FP_ABST
    Figure US2026028135_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are cationic lipids and ionizable lipids illustrating representative hydrophobic-tail architectures for nucleic acid delivery, where in some implementations the nucleic acid is, for example a DNA or an RNA. The lipids are based upon, for example, a symmetric glycerol diether alcohol or a symmetric glycerol diether ester framework. Lipid nanoparticles that include an inventive lipid compound are utilized for example, for the delivery of messenger RNA.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Atorney Docket No. 10025-345W01

[0002] IONIZABLE AND CATIONIC LIPIDS

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS

[0004] This application claims the benefit of priority to U. S. Provisional Application No.

[0005] 63 / 806,344 filed May 15, 2.025, which is hereby incorporated herein by reference in its entirety.

[0006] BACKGROUND

[0007] Ionizable lipids play major roles in protecting nucleic acids, determining their biodistribution, and facilitating their cytosolic transport. Since 2008, many diverse ionizable lipids have been created and used as components of the messenger RNA-lipid nanoparticle (LNP) SARS-CoV-2 vaccine. Currently, ionizable and cationic lipids used for nucleic acid delivery have several major issues: (i) low intracellular' delivery; (ii) poor thermostability; (iii) limited biodegradability; and (iv) laborious synthesis processes. For example, existing RNA formulations including the currently available lipids only achieve approximately 10 % intracellular delivery and require cold storage, as low as -80 °C. This limits therapeutic efficacy, global formulation distribution, and new RNA applications.

[0008] There remains a need for ionizable and cationic lipids that offer different types of symmetric and asymmetric configurations of the tail and amine components. There remains a need for improved ionizable and cationic lipids that are accessible with scalable manufacturing.

[0009] SUMMARY

[0010] In accordance with the purposes of the disclosed compositions and methods as embodied and broadly described herein, the disclosed subject matter relates to compositions and methods of making and use thereof. For example, disclosed herein are ionizable and cationic lipids.

[0011] Additional advantages of the disclosed compositions and methods will be set forth in part in the description which follows, and in part will be obvious from the description. The advantages of the disclosed compositions and methods will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the disclosed systems and methods, as claimed.

[0012] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

[0013] Atorney Docket No. 10025-345W01 BRIEF DESCRIPTION OF THE FIGURES

[0014] The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects of the disclosure, and together with the description, serve to explain the principles of the disclosure.

[0015] Figure 1. Selected ionizable lipids illustrating representative hydrophobic-tail architectures for RNA delivery.

[0016] Figure 2. Comparison of density witbin the range of T = 293.15-343.15 K for tails.

[0017] Figure 3. RI (no) of tails at T = 298.15 K and P = 0.1 MPa.

[0018] Figure 4. Comparison of dynamic viscosities ( / ?) within T = 293.15-343.15 K for tails at 0.1 MPa.

[0019] Figure 5a-Figure 5b. (Figure 5a) Contact angle, (Figure 5b) surface tension measurements of tails.

[0020] Figure 6a-Figure 6d. Representative images of tails (Figure 6a) 1-7, (Figure 6b) 1-8, (Figure 6c) 1-9, and (Figure 6d) 1-10 showing complete wetting on a glass surface.

[0021] Figure 7. Miscibility of tails with common solvents at ambient temperature.

[0022] Figure 8a-Figure 8d. Characteristics of the LNPs formulated with the distinct ionizable lipids. Figure 8a. Hydrodynamic diameter and polydispersity index; Figure 8b. Zeta potential indicative of surface charge; Figure 8c. LNP encapsulation efficiency of mRNA cargo; Figure 8d. Transfection efficiency capabilities of the LNPs.

[0023] Figure 9 depicts a synthetic protocol to prepare disclosed compounds.

[0024] DETAILED DESCRIPTION

[0025] Before the present methods and systems are disclosed and described, it is to be understood that the methods and systems are not limited to specific synthetic methods, specific components, or to particular compositions. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0026] Definitions

[0027] As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from “about” one particular value, and / or to “about” another particular value. When such a range is expressed, another embodiment includes-i from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular valueAtorney Docket No. 10025-345W01 forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.

[0028] “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0029] Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps. “Exemplary” means “an example of’ and is not intended to convey an indication of a preferred or ideal embodiment. “Such as” is not used in a restrictive sense, but for explanatory purposes.

[0030] Disclosed are components that can be used to perform the disclosed methods and systems. These and other components are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these components are disclosed that while specific reference of each various individual and collective combinations and permutation of these may not be explicitly disclosed, each is specifically contemplated and described herein, for all methods and systems. This applies to all aspects of this application including, but not limited to, steps in disclosed methods. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods.

[0031] Compounds disclosed herein may be provided in the form of acceptable salts, for example pharmaceutically acceptable salts. Examples of such salts are acid addition salts formed with inorganic acids, for example, hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids and the like; salts formed with organic acids such as acetic, oxalic, tartaric, succinic, maleic, fumaric, gluconic, citric, malic, methanesulfonic, p-toluenesulfonic, napthalenesulfonic, and polygalacturonic acids, and the like; salts formed from elemental anions such as chloride, bromide, and iodide; salts formed from metal hydroxides, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, and magnesium hydroxide; salts formed from metal carbonates, for example, sodium carbonate, potassium carbonate, calcium carbonate, and magnesium carbonate; salts formed from metal bicarbonates, for example, sodium bicarbonate and potassium bicarbonate; salts formed from metal sulfates, for example, sodium sulfate and potassium sulfate; and salts formed from metal nitrates, for example, sodium nitrate and potassium nitrate.

[0032] The term "alkyl" refers to a radical of a straight-chain or branched hydrocarbon group having a specified range of carbon atoms (e.g., a " Ci-i6 alkyl" can have from 1 to 16 carbonAtorney Docket No. 10025-345W01 atoms). An alkyl group can be a saturated alkyl group or an unsaturated alkyl group, i.e., an alkyl group having one or more carbon-carbon double / triple bonds, i.e., an alkenyl or alkynyl group. Unless specified to the contrary, an “alkyl” group includes both saturated alkyl groups and unsaturated alkyl groups. Unless specified to the contrary, an “alkyl” group includes both substituted alkyl groups and unsubstituted alkyl groups.

[0033] The term "heteroalkyl" refers to an alkyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and / or placed at one or more terminal position (s) of the parent chain. By way of example, a heteroCi ealkyl (which may also be designated a Ci- eheteroalkyl) group includes, but is not limited to, the following structures:

[0034]

[0035] The term “heteroalkyl” preceded by a separate heteroatom refers to a heteroalkyl group bonded through the specified heteroatom. By way of example, a OC] -eheteroalkyl group includes, but it not limited to, the following structures:

[0036]

[0037] When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, " Ci-6 alkyl" is intended to encompass Ci, Cz, C3, C4, C5, Ce, Ci-6, C1-5, C, Ci-3, Ci-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6 alkyl.

[0038] Affixing the suffix "-ene" to a group indicates the group is a polyvalent moiety, e.g., bonded to two or more groups. Alkylene is the polyvalent moiety of alkyl, alkenylene is the divalent moiety of alkenyl, alkynylene is the divalent moiety of alkynyl, heteroalkylene is the divalent moiety of heteroalkyl, heteroalkenylene is the divalent moiety of heteroalkenyl, heteroalkynylene is the divalent moiety of heteroalkynyl, carbocyclylene is the divalent moiety of carbocyclyl, heterocyclylene is the divalent moiety of heterocyclyl, arylene is the divalent moiety of aryl, and heteroarylene is the divalent moiety of heteroaryl (each of which parent groups as defined herein).

[0039] The term "alkoxy" refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.

[0040] The term "aryl" refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 n electrons shared in a cyclicAtorney Docket No. 10025-345W01 array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (" Ce-u aryl"). " Aryl" also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyi or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of an aryl group is independently unsubstituted (an "unsubstituted aryl") or substituted (a "substituted aryl") with one or more substituents.

[0041] " Aralkyl" is a subset of "alkyl " and refers to an alkyl group substituted by an aryl group, wherein the point of attachment is on the alkyl moiety.

[0042] The term "heteroaryl" refers to a radical of a 5-14 membered monocyclic or polycyclic

[0043] (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 n electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-14 membered heteroaryl "). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. " Heteroaryl" includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyi or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. " Heteroaryl" also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic ( aryl / heteroaryl ) ring system. Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2 -indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).

[0044] Exemplary heteroaryl and heterocyclyl rings include: benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyi, carbazolyl, 4aH carbazolyl, carbolinyl, chromanyl, chromenyl, cirmolinyl, decahydroquinolinyl, 2H,6H-l,5,2-dithiazinyl, dihydrofuro[2,3 b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, IH-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquin olinyl, isothiazolyl, isoxazolyl,

[0045] Atorney Docket No. 10025-345W01 methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-l,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-tliiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, tliienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, and xanthenyl.

[0046] Unless specified to the contrary, the alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups defined herein (and the “ene” versions of said groups) may be substituted or unsubstituted. A substituted group includes a non-hydrogen substituent at a position where in the unsubstituted version a hydrogen atom would be found. Substituents include, but are not limited to, halogen, hydroxy, alkyl, heteroalkyl, alkoxy, nitro, cyano, oxo, carbocyclyl, carbocycloalkyl, heterocarbocyclyl, heterocarbocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -NRaRb, -NRaC(=O)Rb, -

[0047]

[0048] context can be the same or different and independently hydrogen, halogen, hydroxyl, alkyl, alkoxy, alkyl, heteroalkyl, amino, alkylamino, dialkylamino, carbocyclyl, carbocycloalkyl, heterocarbocyclyl, heterocarbocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl.

[0049] As used herein, the designation of a polyvalent moiety without specifying the specific order of attachment is intended to cover all possible arrangements. By way of example, a compound represented by the formula:

[0050] A-X-B,

[0051] wherein X is NHC(=0) embraces both:

[0052]

[0053] As used herein, a chemical bond depicted:! ' represents either a single, double, or triple bond, valency permitting. By way of example,

[0054] Atorney Docket No. 10025-345W01

[0055]

[0056] Some compounds disclosed herein may exist as one or more tautomers. Tautomers are interconvertible structural isomers that differ in the position of one or more protons or other labile atom. By way of example:

[0057]

[0058] Unless stated to the contrary, a substituent drawn without explicitly specifying the point of attachment indicates that the substituent may be attached at any possible atom. For example, in a benzofuran depicted:

[0059]

[0060] the substituent may be present at any one of the six possible carbon atoms.

[0061] As used herein, the term “null,” when referring to a possible identity of a chemical moiety, indicates that the group is absent, and the two adjacent groups are directly bonded to one another. By way of example, for a genus of compounds having the formula CH3-X-CH3, if X is null, then the resulting compound has the formula CH3-CH3. A group having the subscript ‘0’ is understood to represent a null group as well. By way of example, in the compound CIl3-(X)z-CH3, if X is CII2 and z is 0, then the compound has the formula CII3-CH3.

[0062] A bracketed functional group with a subscripted variable should be understood to denote the number of repeated bracketed groups present. For example, a number that is selected from 0 or 1 should be interpreted as follows:

[0063]

[0064] In certain instances, two or more variable groups may together form a ring. It is understood that any depicted atoms separated the identified groups will themselves form part of the ring:

[0065]

[0066] Atorney Docket No. 10025-345W01

[0067] When the variable groups are substituted on an aromatic system the new ring will be a fused ring, and unless specified to the contrary may be either aromatic or non-aromatic, carbocyclic or heterocyclic:

[0068]

[0069] The ring may further be defined by the number of carbon atoms in the specific ring formed by the variable groups, which includes the atoms separating the variable groups:

[0070]

[0071] yl

[0072] Each of the above results when R1and R ' together form a six membered (or six atom) ring. Other rings, including 3, 4, 5, 7, and 8-member rings may also be formed, and may be further limited by a specified number of carbon atoms. Although the singular “a ring” may be used to define the group, unless specified to the contrary both the ring may be a monocyclic ring or a polycyclic ring:

[0073]

[0074] R1and R2form a: monocyclic ring polycyclic ring

[0075] Unless stated to the contrary, a formula with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplates each possible isomer, e.g., each enantiomer, diastereomer, and meso compound, and a mixture of isomers, such as a racemic or scalemic mixture. Unless stated to the contrary, a formula depicting one or more stereochemical features does not exclude the presence of other isomers.

[0076] Compositions and methods of making and use thereo f

[0077] Disclosed herein are compounds of Formula (1):

[0078]

[0079] [Formula (1)],

[0080] or pharmaceutically acceptable salt thereof, wherein

[0081] is a single bond or double bond;

[0082] Zlais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that — connected to Zais a single bond when Zlais not null;

[0083] Zlbis null, Cz-salkylene, or C2-8alkyleneNRnlC2-8alkylene, wherein Rnlis H or Ct-4alkyl;

[0084] R1is a group having the formula:

[0085] Atorney Docket No. 10025-345W01

[0086]

[0087] wherein

[0088] R2is Ci-4alkyl or a group having the formula:

[0089]

[0090] wherein

[0091] Z2ais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that — connected to Z2ais a single bond when Z2ais not null;

[0092] Z2bis null, C2-salkylene, or C2-8alkyleneNRn2C2-8alkylene, wherein Rn2is II or Ci 4alkyl;

[0093] R3is Ci-4alkyl, absent, or a group having the formula:

[0094]

[0095] wherein

[0096] Z3ais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Z3ais a single bond when Z3ais not null;

[0097] Z3bis null, C2-salkylene, or C^-salkyleneNR^C^-salkylene, wherein Rn3is II or Ci 4alkyl;

[0098] R' is Ci 4alkyl or a group having the formula:

[0099]

[0100] Ztais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Ztais a single bond when Ztais not null;

[0101] Ztbis null, C2-8alkylene, or C2-8alkyleneNRutC2-8alkylene, wherein Rntis H or Ci-4alkyl;

[0102] Y1is null, C -salkylene, or C2-8alkyleneNRylC2-8alkylene, wherein Rylis H or Ci-4alkyl; or when Zlaand Zlbare null, and is a double bond, then R1can also be absent;

[0103] R4is Ci-ialkyl or a group having the formula:

[0104]

[0105] wherein

[0106] Z4ais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that — connected to Z4ais a single bond when Z4ais not null;

[0107] Atorney Docket No. 10025-345W01

[0108] Z4bis null, C2-8alkylene, or C2-8alkyleneNRn4C2-8alkylene, wherein Rn4is H or Ci-4alkyl;

[0109] Y4is C2-salkylene or C2-8alkyleneNRy4C2-8alkylene, wherein R-4is II or Ci.4alkyl;

[0110] R4ais Ci-4alkyl or a group having the formula:

[0111]

[0112] Z4aais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that — connected to Z4aais a single bond when Z4aais not null;

[0113] Z4bais null, C2-8alkylene, or C2-salkyleneNR4baC2-8alkylene, wherein R4bais H or Ci-

[0114] 4alkyl;

[0115] R4bis Ci-4alkyl or a group having the formula:

[0116]

[0117] Z4abis null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Z4abis a single bond when Z4abis not null;

[0118] Z4bbis null, C2-salkylene, or C2-salkyleneNR4bbC2-8alkylene, wherein R4bbis H or C1-4alkyl;

[0119] R4tis Ct-4alkyl or absent;

[0120] R5is Ci 4alkyl or a group having the formula:

[0121]

[0122] wherein

[0123] Z5ais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Z5ais a single bond when Z5ais not null;

[0124] Z5bis null, C2-salkylene, or C2-8alkyleneNR5bC2-8alkylene, wherein R5bis H or Ci-4alkyl;

[0125] Y5is C2-salkylene or C2-salkyleneNRy5C2-8alkylene, wherein Ry5is II or Ci-4alkyl;

[0126] R3ais Ci-ralkyl or a group having the formula:

[0127]

[0128] Z5aais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Z5aais a single bond when Z5aais not null;

[0129] Z5bais null, C2-8alkylene, or C2-salkyleneNR5baC2-8alkylene, wherein R5bais H or Ci- 4alkyl;

[0130] Attorney Docket No. 10025-345W01

[0131] R5bis Ci-4alkyl or a group having the formula:

[0132]

[0133] Z5abis null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that — connected to Z5abis a single bond when Z5abis not null;

[0134] Z5bbis null, C2-salkylene, or C2-8alkyleneNR5bbC2-8alkylene, wherein R5bbis H or Cn

[0135] 4alkyl;

[0136] R5tis Ci-4alkyl or absent;

[0137] wherein when any two or more of R2, R3, and R* are Ci-4alkyl, said R“, R3, and R' may together with the nitrogen to which they are attached form a C2-i2heterocyclic ring;

[0138] wherein when any two or more of R4, R5, and R3are Ci-4alkyl, said R4, R5, and Rsmay together with the nitrogen to which they are attached form a C2-i2heterocyclic ring; and wherein when any two or more of R4a, R4b, and R4tare Ci-4alkyl, said R4a, R4b, and R4' may together with the nitrogen to which they are attached form a C2-i2heterocyclic ring;

[0139] wherein when any two or more of R5a, R5b, and R5tare Ci-4alkyl, said R5a, R5b, and R5tmay together with the nitrogen to which they are attached form a C2-i2heterocycIic ring; and lipid is in each case independently a Ce-soalkyl group

[0140] In some implementations lipid is in each case independently a ( ■ -alkyl group, Ce-isalkyl group, Ce-rtalkyl group, Ce-nalkyl group, or Ce-ioalkyl group.

[0141] In some implementations one or more of the lipid groups in the compound of Formula (1) can be a linear C6-3oalkyl group, ( <, --alkv I group, Ce-isalkyl group, Ce-i4alkyl group, Ce- alkyl group, or Ce-ioalkyl group. In some implementations one or more of the lipid groups in the compound of Formula (1) can be a branched Ce-3oalkyl group, 0,22a! ky I group, Cg-isalkyl group, C6-i4alkyl group, Ce-nalkyl group, or Ce-ioalkyl group. In some implementations one or more of the lipid groups in the compound of Formula (1) can be a saturated Ce-soalkyl group, Cg-22alkyl group, Ce-isalkyl group, Cg-i4alkyl group, Cg-i2alkyl group, or Cg-ioalkyl group. In some implementations one or more of the lipid groups in the compound of Formula (1) can be an unsaturated Cg-3oalkyl group, ( 1, --alkyl group, Cg-isalkyl group, Cg-ualkyl group, Cg-nalkyl group, or Cg-ioalkyl group. In some implementations one or more of the lipid groups in the compound of Formula (1) can be an unsaturated Cg-3oalkyl group,..-.-alkyl group, Cg-isalkyl group, Cg-ualkyl group, Cg- alkyl group, or Cg-ioalkyl group having one, two, three, four, or five carbon-carbon double bonds. In some implementations one or more of the lipid groups in the compound of Formula (1) can be an unsaturated Cg-3oalkyl group,

[0142]

[0143] - -alky! group, Cg-isalkyl group, Cg-ualkyl group, Cg-nalkyl group, or Cg-ioalkyl group having one, two, or three carbon-Attorney Docket No. 10025-345W01 carbon double bonds. In some implementations one or more of the lipid groups in the compound of Formula (1) can be an unsaturated Ce-3oalkyl group, Ce-22alkyl group, Ce-isalkyl group, Ce- i4alkyl group, Ce- alkyl group, or Ce-ioalkyl group having one, two, or three carbon-carbon double bonds in the cis configuration. In some implementations each of the lipid groups in the compound of Formula (1 ) can be a saturated Ce-3oalkyl group, Ce-22alkyl group, Cg-isalkyl group, Ce-ualkyl group, C6-i2alkyl group, or Ce-ioalkyl group. In some implementations each of the lipid groups in the compound of Formula (1) can be an unsaturated C6-3oalkyl group, C6-2?.alkyl group, Ce- is alkyl group, Ce-walkyl group, Ce- alkyl group, or Ce-ioalkyl group.

[0144] In some implementations the one or more of the lipid groups can be derived from fatty acids. In some implementations one or more of the lipid groups can be derived from crotonic acid, lauric acid, myristic acid, palmitic acid, stearic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, vaccenic acid, gadoleic acid, eicosenoic acid, erucic acid, linoleic acid, eicosadienoic acid, docosadienoic acid, linolenic acid, pinolenic acid, eleostearic acid, dihomo-y-linolenic acid, eicosatrienoic acid, tetra-un saturated fatly acids, stearidonic acid, arachidonic acid, eicosatetraenoic acid, adrenic acid, bosseopentaenoic acid, eicosapentaenoic acid, ozubondo acid, sardine acid, tetracosanolpentaenoic acid, docosahexaenoic acid, herring acid, petroselinic acid, paullinic acid, gondoic acid, erucic acid, brassidic acid, nervonic acid, arachidonic acid, or a combination thereof.

[0145] In some implementations, each of the lipid groups is the same. In other implementations, not all the lipid groups are the same.

[0146] In some implementations Zlaand Zlbare null, i.e., a compound having the formula:

[0147] Lipid-

[0148] Lipid—

[0149]

[0150] In some implementations Zlaand Zibare null, is a single bond and each of R2, R3, and Rlare Cnralkyl, i.e., a compound of formula:

[0151]

[0152] In some implementations Zlaand Zlbare null, and is a double bond, and R3and R4are absent, i.e., a compound of formula:

[0153]

[0154] Such imine compounds can include tautomeric isomers as well, i.e.:

[0155] Atorney Docket No. 10025-345W01

[0156]

[0157] combination thereof.

[0158] Unless specified to the contrary the depiction of one tautomeric form embraces the other tautomeric form as well.

[0159] In some implementations Zlais O(C=O), Zibis C2-salkylene (preferably C2alkylene), R2, R‘ are Ci-4alkyl, and R3is absent or Cwalkyl, i.e., a compound having the formula:

[0160]

[0161] In some implementations Zlais O(C=O), Z!bis Ci-salkylene (preferably Czalkylene), R2is a group having the formula:

[0162]

[0163] Z2ais OC(=O);

[0164] Z2bis Cz-salkylene (preferably C alkylene);

[0165] R' is Ci 4alkyl; and

[0166] R3is absent, i.e., a compound having the formula:

[0167] id

[0168]

[0169] id

[0170] Ill some implementations Zlais O(C=O), Z!bis Ci-salkylene (preferably Cialkylene), R is a group having the formula:

[0171]

[0172] Z2ais OC(=O);

[0173] Z2bis Cz-salkylene (preferably C alkylene);

[0174] R3is absent;

[0175] R' is a group having the formula:

[0176]

[0177] Attorney Docket No. 10025-345W01

[0178] Z1ais OC(=O); and

[0179] Ztbis C2-8alkylene (preferably Cialkylene); i.e., a compound having the formula:

[0180]

[0181] In some implementations Zlais O(C=O), Zlbis C2-salkylene (preferably C2alkylene), R2up having the formula:

[0182]

[0183] Z2ais OC(=O);

[0184] Z2bis C2-salkylene (preferably Cjalkylene);

[0185] R3is absent;

[0186] R' is a group having the formula:

[0187]

[0188] Y1is C2-salkylene;

[0189] R4is Ci-4alkyl;

[0190] R5is Ci-4alkyl; and

[0191] Rsis Ci-4alkyl; i.e., a compound having the formula:

[0192]

[0193] In some implementations Zlais O(C=O), Zlbis C2-salkylene (preferably C2alkylene), R2up having the formula:

[0194] Atorney Docket No. 10025-345W01

[0195]

[0196] Z2ais OC(=O);

[0197] Z2bis CO-salkylene (preferably C.2alkylene);

[0198] R;is absent;

[0199] R!is a group having the formula:

[0200] i zR4

[0201] HY1-N-RS

[0202] 1R5

[0203] Y1is Cz-salkylene;

[0204] R4is a group having the formula:

[0205]

[0206] wherein

[0207] Y4is Cz-salkylene;

[0208] R4ais a group having the formula:

[0209]

[0210] Z4aais OC(=O),

[0211] Z4bais C2-salkylene (preferably C2alkylene);

[0212] R4bis a group having the formula:

[0213]

[0214] Z4abis OC(=O);

[0215] Z4bbC2-salkylene (preferably C2alkylene);

[0216] R4' is absent;

[0217] R3is a group having the formula:

[0218] R5a

[0219] I— Y5-N— R5t

[0220] 5b

[0221] wherein

[0222] Y5is C2-8alkyleni

[0223] Atorney Docket No. 10025-345W01

[0224] R5ais a group having the formula:

[0225]

[0226] Z5aais 0C(=0);

[0227] Z5bais C2-salkylene (preferably Cdalkylene);

[0228] R5bis a group having the formula:

[0229]

[0230] Z5abis OC(=O);

[0231] Z5bbis Cj-salkylene (preferably C2alkylene): and

[0232] R5tis absent; i.e. a compound having the formula:

[0233]

[0234] In some implementations, each of the lipid-containing moieties depicts above can have the formula:

[0235] Lipid

[0236] Lipid

[0237]

[0238] wherein Lipid 1 and Lipid 2 are not the same.

[0239] In some implementations Lipid 1 is linear Ce-soalkyl group, C6-22alkyl group, Ce-isalkyl group, Ce-ualkyl group, Ce-nalkyl group, or Ce-ioalkyl group and Lipid 2 is a branched Cs-soalkyl group, C6-22alkyl group, Cg-isalkyl group, Ce-ualkyl group, Ce-nalkyl group, or Ce-ioalkyl group.

[0240] In some implementations Lipid 1 is a saturated Ce-soalkyl group, Ce-22alkyl group, Ce- isalkyl group, Ce-ualkyl group, Ce-nalkyl group, or Ce-ioalkyl group, and Lipid 2 is an unsaturated Ce-soalkyl group, C6-22alkyl group, Ce-tsalkyl group, Ce-ualkyl group, Ce-nalkyl group, or Ce-icalkyl group. In some implementations Lipid 1 is a saturated Cs soalkyl group, Ce 22alkyl group, Ce-isalkyl group, Ce-ualkyl group, Ce-i2alkyl group, or Ce-ioalkyl group, and Lipid 2 is an unsaturated Ce-soalkyl group, C6-22alkyl group, Ce-isalkyl group, Ce-ualkyl group, Ce- alkyl group, or Ce-ioalkyl group.

[0241] Atorney Docket No. 10025-345W01

[0242] In some implementations Lipid 1 is a saturated C6-3oalkyl group, Chalky! group, Cc,-isalkyl group, Ce- walkyl group, Ce-nalkyl group, or Ce-ioalkyl group, and Lipid 2 is an unsaturated Cg-soalkyl group, Cg-22alkyl group, Cg-isalkyl group, CLwalkyl group, Ce-i2alkyl group, or Ce-ioalkyl group having one, two, three, four, or five carbon-carbon double bonds.

[0243] In some implementations Lipid 1 is a saturated Cg-3oalkyl group, Cg-22alkyl group, (L isalkyl group, Ce-ualkyl group, Cg alkyl group, or Ce loalkyl group, and Lipid 2 is an unsaturated C'6-3oalkyl group, (??alkyi group, Ce-isalkyl group, Ce-ualkyl group, Ce-nalkyl group, or Ce-ioalkyl group having one, two, or three carbon-carbon double bonds.

[0244] In some implementations Lipid 1 is a saturated Ce-3oalkyl group, Ce^alkyl group, ( •, isalkyl group, Ce-walkyl group, Ce nalkyl group, or Ce-ioalkyl group, and Lipid 2 is an unsaturated Ce-3oalkyl group, C6-22alkyl group, Ce-isalkyl group, Ce-ualkyl group, Cs- alkyl group, or Ce-ioalkyl group having one, two, or three carbon-carbon double bonds in the cis configuration.

[0245] In some implementations both Lipid 1 and Lipid 2 are unsaturated Ce-soaikyl groups, Ce-22alkyl groups, Ce-isalkyl groups, Ce-ualkyl groups, Ce-nalkyl groups, or Ce-ioalkyl groups. In some implementations both Lipid 1 and Lipid 2 are unsaturated Ce-soalkyl groups, Ce-22alkyl groups, Ce-isalkyl groups, Ce-walkyl groups, Ce-nalkyl groups, or Ce-ioalkyl groups having one, two, three, four, or five carbon-carbon double bonds. In some implementations both Lipid 1 and Lipid 2 are unsaturated Ce-3oalkyl groups, Ce-22alkyl groups, Ce-isalkyl groups, Ce-walkyl groups, Ce- alkyl groups, or Ce-ioalkyl groups having one, two, or three carbon-carbon double bonds. In some implementations both Lipid 1 and Lipid 2 are unsaturated Ce-3oalkyl groups, Ce-22alkyl groups, Ce-isalkyl groups, Ce-ualkyl groups, Ce-nalkyl groups, or Ce-ioalkyl groups having one, two, or three carbon-carbon double bonds in the cis configuration.

[0246] In some implementations, the disclosed compounds may be prepared by reaction of ammonia, primary amine, or secondary amine compound with a compound having the formula:

[0247]

[0248] wherein lipid is as defined above, Ryis C2-8alkylene, and X is a suitable leaving group, for example Cl, Br, I, OMs, or OTs.

[0249] In some implementations the ammonia, primary amine, or secondary amine compound has the formula:

[0250] Atorney Docket No. 10025-345W01

[0251]

[0252] wherein

[0253] Rais H, C1-4alkyl, optionally substituted by NID, NHCwalkyl, or N(Ci-4alkyl)2;

[0254] Rbis H, C1-4alkyl, optionally substituted by NH2, NHCi-ialkyl, or N(Ci-4alkyl)2;

[0255] Rcis H, C1-4alkyl, optionally substituted by NH2, NHCi.4alkyl, or N(Ci-4alkyl)2.

[0256] In some implementations, Rais substituted by NH2, NHCi^alkyl, or N(Ci-4alkyl)2, and Rais a linear < ‘?:<d k I. with the amine substitution occurring on the terminal carbon of the chain.

[0257] In some implementations, Rbis substituted by NH2, NHCi-4alkyl, or N(Ci-4alkyl)2, and Rbis a linear C2-4alkyl, with the amine substitution occurring on the terminal carbon of the chain.

[0258] In some implementations, Rcis substituted by NH2, NHCb4alkyl, or N(Ci-4alkyl)2, and Rcis a linear C2-4alkyl, with the amine substitution occurring on the terminal carbon of the chain.

[0259] In some implementations, Rais H and Rband Rcare each Ci alkyl.

[0260] In some implementations, Rais Ci-4alkyl and Rband Rcare each C1-4alkyl substituted by NH2, NHCi-4alkyl, or N(C1-4alkyl)2, preferably NH2.

[0261] In some implementations, Raand RbC1-4alkyl and Rcis C1-4alkyl substituted by NH2, NHC1-4alkyl, or N(C1-4alkyl)2, preferably NH2.

[0262] In some implementations the ammonia, primary amine, or secondary amine compound is:

[0263]

[0264] A No disclosed herein are pharmaceutical compositions comprising the disclosed compounds and an active agent. In some implementations the active agent is a therapeutic agent, a diagnostic agent, a cell, or an immunomodulatory agent, for example a vaccine.

[0265] In some implementations the active agent is a nucleic acid, for example DNA or RNA, for example single- stranded DNA, double stranded DNA, encapsulated DNA, complexed DNA, naked RNA, messenger RNA (mRNA), encapsulated RNA, tRNA, short interfering RNA (siRNA), antisense RNA (asRN / A), amplify mRNA (saRNA), double stranded RNA (dsRNA), micro-RNA (miRNA), self-guide RNA (gRNA), cRNA, or a combination thereof.

[0266] In some implementations the active agent is an RNA, e.g. mRNA that encodes a functional secreted polypeptide.

[0267] Atorney Docket No. 10025-345W01 In some implementations the active agent is an RNA, e.g. mRNA, that encodes an enzyme which is abnormally deficient in an individual with a lysosomal storage disorder.

[0268] In some implementations the active agent is an RNA, e.g. mRNA that encodes a functional erythropoietin or functional a-galactosidase polypeptide.

[0269] In some implementations the active agent is a modified RNA, e.g., modified mRNA.

[0270] Modified RNA can include any one or more of the following modifications: modification of the 3’ end or 5’ end with a capping group or replacement of the terminal phosphate, modification of the phosphate ester bond, for example replacement of one or more oxygen atoms with nitrogen or sulfur or complete replacement of the phosphate ester moiety with a different linking group, modification of the ribose sugar, for example removal of the 2’ hydroxyl group, replacement of a nucleobase with a non-canonical nucleobase.

[0271] In some implementations the active agent is an RNA molecule having a modification of the 5' untranslated region of said RNA molecule. In some implementations the modification includes the inclusion of a cap structure. In some implementations the modification is of the 3' untranslated region of said RNA molecule. In some implementations the modification includes the inclusion of a poly A tail.

[0272] Also disclosed herein are lipid nanoparticles (LNP) that include at least one compound disclosed herein. The LNPs can further include a non-ionizable lipid, neutral lipid, PEG lipid and / or helper lipid. In some implementations the LNPs can include a non-ionizable lipid and / or a PEG-modified lipid. In some implementations the LNPs can include a helper lipid such as distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylethanolamine (DOPE), dipalmitoylphosphatidylcholine (DOPC), phosphatidylcholine (PC), 1,2-dilinoleoyl-sn-glycero- 3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2- dipahnitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), and mixtures thereof.

[0273] In some implementations the compositions can further include a cryoprotectant and / or a buffer.

[0274] The lipid nanoparticles can be provided as lyophilized compositions, optionally in combination with one or more active agents as described above. The lyophilized composition may be reconstituted in a suitable aqueous vehicle and administered to a subject in need of the active agent.

[0275] The compositions disclosed herein are useful for selectively delivering active agents to specific cell types. In some implementations composition can be used to selectively target is selected from the group consisting of hepatocytes, epithelial cells, hematopoietic cells, epithelialAtorney Docket No. 10025-345W01 ceils, endothelial ceils, lung cells, hone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary ceils, synovial lining cells, ovarian ceils, testicular cells, fibroblasts, B ceils, T cells, reticulocytes, leukocytes, granulocytes, or tumor cells.

[0276] A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

[0277] The examples below are intended to further illustrate certain aspects of the systems and methods described herein, and are not intended to limit the scope of the claims.

[0278] EXAMPLES

[0279] The following examples are for the purpose of illustration of the invention only and are not intended to limit the scope of the present invention in any manner whatsoever.

[0280] Example 1

[0281] Synthesis of symmetric glycerol diether alcohol [R, 0, R]. A primary (1°) alcohol (6 eq.) was added to a suitable round bottom flask loaded with NaOH powder (1.4 eq. ), which was then heated to 65 °C and stirred for 1 h, followed by drop wise addition of epichlorohydrin (1.0 eq.). The reaction was allowed to run overnight before cooling to RT. The excess of 1° alcohol was removed by rotary evaporation under reduced pressure. 600 mL Et2O was then added to the crude product, and the mixture was neutralized by 1 M HC1 and dried over MgSC The solids were filtered, and Et2O was removed by rotary evaporation under reduced pressure, followed by vacuum distillation to afford [R, 0, RJ.

[0282] Synthesis of symmetric glycerol diether alcohol [R, 0, R]. A primary (1°) alcohol (6 eq.) was added to a suitable round bottom flask loaded with NaOH powder (0.2 eq.), which was then heated to 65 °C and stirred for 1 h, followed by dropwise addition of glycidyl ethers (1.0 eq.). The reaction was allowed to run overnight before cooling down to RT'. The excess of primary (1°) alcohol was removed by rotary evaporation under reduced pressure. 600 mL Et2O was then added to the crude product, and the precipitate was then filtered. The organic phase was washed sequentially with 2 x 80 ml, DI water and 3 x 60 mL saturated aq. NaHCOs solution.

[0283] The organic layer was separated and dried over MgSCL. The solids were filtered, and Et2O was removed by rotary evaporation under reduced pressure, followed by vacuum distillation to afford [Ri, 0, R2I.

[0284] Synthesis of symmetric and asymmetric glycerol diether ester [R, Ester, R] and [Ri, Ester, R2]. [Ri, 0, R2] or [R, 0, R] (1.0 eq) and 0.1 eq of DMAP were introduced to a 250 mL round-bottom flask. CHCI3 (60 mL) and EtaN (1.5 eq) were added under N?. atmosphere,

[0285] Atorney Docket No. 10025-345W01 followed by the dropwise addition of 1.1 eq of acrylic anhydride (AA) at room temperature. The final mixture was heated at 45 °C while stirring for 24 h. The solvent was removed under vacuum, and the white solid was filtered. The filtrate was diluted with CHCL and washed with saturated NaHCCL and water several times, before drying over MgSO4. The crude product was purified using column chromatography on silica gel with the eluent solvents

[0286] Synthesis of symmetric and asymmetric lipids. The ester portion of the lipids was synthesized at a 3:1 ratio of acrylate to amine, without using any solvent. The mixture was heated to 90 °C while stirring for four days. The crude product was purified through column chromatography on silica gel, using eluent solvents until the reaction was complete, as monitored by thin-layer chromatography (TLC).

[0287] Synthesis of [R, Cl, R]. In a 500 mL round-bottom flask equipped with a stir bar, [R, 0, R] (1 eq.) was added in 100 mL of CHCL with a catalytic amount of pyridine (0.5 ml,). The reaction was stirred at room temperature, and SOCI2 (1.2 eq.) was added dropwise over a period of 30 min. After this time, the dropping funnel was replaced by a condenser, and the reaction was heated at reflux for 48 h. The reaction mixture was directly distilled to give the pure compound and stored over 3A molecular' sieves to further reduce water content.

[0288] Synthesis of [R, NH2, R]. [R, Cl, R] (1.0 eq.) in 10 wt. of 25% aqueous ammonia was heated for 3 hours in a Parr reactor at 170° C. The excess ammonia was largely evaporated off. The aqueous solution was treated with solid sodium hydroxide. The [R, NH2, R] was extracted with CHCL. The extract was freed from solvent and distilled under vacuum to get the pure product.

[0289] Example 2 - Glycerol-Derived Tail Precursors as Modular Building Blocks for Ionizable Lipids and Functional Amphiphiles

[0290] Abstract: Glycerol valorization has largely focused on small oxygenated molecules, whereas its extension into larger, function-oriented architectures remains underdeveloped. Here, a modular glycerol-derived tail precursor platform that connects renewable small-molecule chemistry with amphiphilic architectures relevant to ionizable lipid design is reported. Ten glycerol-diether alcohols were synthesized from epichlorohydrin or glycidyl ethers to systematically vary key hydrophobic descriptors, including branching, unsaturation, chain length, and symmetry. These compounds provide a unified scaffold for structure-property analysis while retaining a secondary alcohol handle for divergent functionalization.

[0291] Measurements of density, refractive index, viscosity, contact angle, surface tension, and miscibility show that tail architecture measurably influences molecular packing, polarizability,Atorney Docket No. 10025-345W01 fluidity, wetting, and interfacial behavior. The platform was further advanced to a representative piperazine-containing ionizable lipid, demonstrating the feasibility of converting glycerolderived tail precursors into larger amphiphilic molecules. Finally, the developed ionizable lipids were utilized to construct lipid nanoparticles (LNPs) via microfluidics for messenger RNA (mRNA) delivery, and the physicochemical and biological properties of the formulations were systematically evaluated. Overall, this work establishes glycerol-derived tails as renewable and synthetically extensible building blocks for ionizable lipids, thiol-functionalized derivatives, and broader classes of functional materials.

[0292] Introduction. Glycerol is an abundant renewable feedstock produced in large quantities as a low-value byproduct of biodiesel manufacture, and its efficient valorization remains a central challenge in sustainable chemistry. As biodiesel production continues to expand, the associated oversupply of glycerol has intensified the need to convert this readily available feedstock into higher-value chemicals and materials, both to improve process economics and to broaden the utility of biomass-derived carbon resources. Recent reviews have therefore emphasized glycerol not only as a waste-derived co-product, but also as a versatile platform molecule for sustainable chemical synthesis, polymer production, and advanced materials development.1-5In recent work, this challenge was addressed by synthesizing small glycerol¬ derived molecules from activated intermediates, such as epichlorohydrin (ECH) and glycidyl ethers. These intermediates enabled access to structurally diverse glycerol -based compounds, including l,3-diether-2-ketones,6’7multifunctional solvents,8, 9and 1,3-dimethoxyacetone,6demonstrating that modest structural modifications of the glycerol scaffold can significantly influence polarity, viscosity, volatility, and CO? affinity.10 12More recently, this chemistry was extended to symmetric and nonsymmetric l,3-diether-2-alkenes, which were designed as platform molecules rather than end products.13-15The symmetric alkene study demonstrated that glycerol-derived alkenes are amenable to downstream transformations, including bromination and other vinyl functionalizations.14In the complementary nonsymmetric alkene study, thiol-ene coupling was directly demonstrated, and the resulting thioethers were shown to serve as intermediates for more complex glycerol-derived structures.13In particular, this body of work established that activated glycerol forms provide a practical and modular-entry point to chemically distinct product classes while preserving the advantages of renewable origin and scaffold-level tunability.

[0293] Taken together, these studies establish a clear progression in the research program, from small glycerol-derived molecules to larger, function-oriented architectures built on glycerol¬ based motifs. This trajectory is further reinforced by recent serinol-based studies, in which

[0294] Atorney Docket No. 10025-345W01 glycerol-inspired chemistry was extended to more sophisticated amine-containing frameworks for water-lean CO? capture.16, 17In those systems, systematic variation of peripheral substitution and molecular symmetry enabled control over viscosity, CO? loading, and switchable-solvent behavior, demonstrating that glycerol- and serinol-derived motifs can support more complex and application-directed molecular designs rather than only simple solvents.16, 17The present work advances tliis progression further by moving into amphiphilic structures relevant to molecular transport and delivery.

[0295] RNA-based therapeutics hold considerable promise for the treatment of a wide range of conditions, including infectious diseases, metabolic and neurological disorders, cancers, and heritable diseases. Realizing this potential, however, depends critically on effective delivery systems.18, 19Ionizable lipids (Figure 1) and lipid nanoparticles (LNPs) are therefore of particular interest because their performance is highly sensitive to hydrophobic tail structure. Recent studies have shown that tail unsaturation, branching, chain length, and tail multiplicity can strongly influence membrane packing, endosomal escape, intracellular trafficking, and in vivo protein expression.19 24Unsaturated tails generally increase membrane fluidity and favor nonbilayer phase behavior, thereby facilitating membrane destabilization and cytosolic cargo release.19-21Branched tails have frequently outperformed their linear counterparts and have been linked to improved acidic ionization behavior, more favorable intracellular trafficking, and enhanced in vivo efficacy.22, 26Tail length can also exert pronounced, cargo-dependent effects,23while multi-tail architectures may enhance endosomal disruption by promoting a more cone- shaped hydrophobic profile.24Collectively, these studies provide a useful design framework for the present work, but they also reveal a practical limitation of many reported systems: the hydrophobic motifs are often developed primarily for screening-oriented delivery libraries rather than from a broader synthetic platform that can be extended to other classes of functional molecules.

[0296] In tliis context, strategies which use glycerol-derived tails offer several distinct advantages. First, they originate from a renewable and structurally well-defined glycerol scaffold rather than from conventional hydrophobic tail feedstocks.6, 13, 14Also, the precursors for the tails can be obtained from natural products or waste materials (e.g., breakdown of dialkyl phthalate plasticizers). Second, the common glycerol -diether framework enables systematic variation of linearity versus branching, saturation versus unsaturation, tail length, and molecular symmetry while preserving a common synthetic entry point, making structure-property comparisons more direct and chemically interpretable. Third, these intermediates are not restricted to delivery- oriented lipid synthesis. 'The same scaffold can be advanced toward glycidyl -functionalized

[0297] Attorney Docket No. 10025-345W01 amphiphiles, ionizable lipids, sulfur-containing derivatives or alkene-bearing molecules suitable for thiol-ene postfunctionalization.14This feature distinguishes the present platform from many screening-oriented lipid libraries, where hydrophobic motifs are often optimized for a single nanoparticle format. Accordingly, these structures should be viewed not simply as new lipid tails, but as renewable, modular' glycerol-based building blocks that connect ionizable lipid synthesis with broader functional-molecule and materials design.

[0298] This platform-level design is embodied in compounds 1-1 to 1-10 (Table 1), which share a glycerol -diether alcohol scaffold but differ in the identity and symmetry of the two hydrophobic substituents. The library includes symmetric saturated linear tails

[0299] (1-1), symmetric saturated branched tails (1-4), symmetric branched unsaturated tails with different degrees of unsaturation (1-2 and 1-3), and asymmetric mixed-tail

[0300] structures (1-5 to 1-10) that combine chain-length, branching, and unsaturation

[0301] differences within a single molecule. Thus, the library does not simply compare isolated structural variables such as branching or unsaturation. Instead, it defines a controlled glycerol-based chemical space in which several delivery -relevant hydrophobic

[0302] descriptors can be varied independently or in combination while the central scaffold is preserved. This design parallels key descriptors emphasized in recent LNP studies,19’21123. 25, 26 butjyjggg from a renewable glycerol -derived synthetic platform rather than from conventional lipid screening alone.

[0303] Table 1. Structures and identifiers of glycerol-derived tail precursors and the representative ionizable lipid synthesized in this work.

[0304]

[0305] Attorney Docket No. 10025-345WO1

[0306]

[0307] The synthetic design also makes the platform chemically divergent rather than single¬ purpose. As shown in Scheme 1, the common glycerol-diether alcohol intermediate can be directed toward ionizable lipid synthesis or redirected to glycerol-derived thiols. In addition, several members of the tail library contain alkene functionality, providing complementary handles for thiol -ene chemistry and other postfunctionalization strategies. Together with recent nonsymmetric alkene and glycerol-derived methacrylate studies1, 27, 28this route demonstrates that glycerol-derived tail precursors can serve as shared intermediates for delivery-oriented amphiphiles, sulfur-containing derivatives, and other functional materials. Thus, the present work extends glycerol-derived small-molecule chemistry into a broader synthetic framework for larger multifunctional architectures.

[0308] Attorney Docket No. 10025-345W01

[0309]

[0310] Scheme 1. Divergent synthesis of glycerol-derived tails, ionizable lipids, and glycerol-derived thiols.

[0311] Materials and methods

[0312] Materials and instruments. 1 -Heptanol (99% min), butyl glycidyl ether (BGE,

[0313] 98% min), citronellol (97%), ethanol (EtOH, 99% min), thiourea (99% min), sodium hydroxide (NaOH, 97%), sodium bicarbonate (NaHCCE, 99.7%), 2 -Ethylhexyl glycidyl (98%), and aqueous HC1 (36.5—38%) were purchased from VWR. (±)-ECH (99%) and chloroform-d (CDCh, 99.8%) were purchased from BeanTown Chemical. Anhydrous magnesium sulfate (MgSCh, 98.0%) was obtained from EMD Millipore, and anhydrous diethyl ether (Et2(), 99.0%) from J. T. Baker. Nerol (97%), pyridine (Py, 99.0%), and (+)- 2-Ethyl-l -hexanol (99.0%) were purchased from Thermo Scientific. DMSO-ifc (99%

[0314] with 0.05% v / v TMS) was purchased from Cambridge Isotope Labs. Allyl glycidyl ether (AGE, 99% min), prenol (99.0%), 1,4-piperazinediethanamine (95%), and 3 A molecular sieves (3.2 mm pellets) were obtained from Sigma-Aldrich. All chemicals were used without further purification.

[0315] All products were characterized by 11 NMR spectroscopy (Bruker Ascend 500 and Avance 360), and final ionizable lipid products were further analyzed by13C NMR spectroscopy. High-resolution mass spectra (HRMS) were obtained on a. ThermoFisher Scientific Q-TOF mass spectrometer in ESI mode. Density, viscosity, and water content were measured at ambient pressure using a Mettler Toledo DM45 densimeter, a Brookfield DV-II+ Pro viscometer, and a Mettler Toledo C20S Karl Fischer titrator, respectively, following established protocols.29Refractive index (RI) was determined with a Mettler Toledo refractometer at 1 atm and 298.15 K.13Miscibility was assessed by combining 3 mL of synthesized compound with 3 mL of test solvent in a glass vial, vortexing for 30 s, and equilibrating at room temperature for 30 min.

[0316] Atorney Docket No. 10025-345W01

[0317] Samples that remained clear and homogeneous were classified as miscible; otherwise, they were deemed immiscible.13Miscibility was assessed by combining 3 mL of synthesized compound with 3 mL of test solvent in a glass vial, vortexing for 30 s, and equilibrating at room temperature for 30 min. Samples that remained clear and homogeneous were classified as miscible: otherwise, they were deemed immiscible.13Contact angle measurements were performed to evaluate solvent hydrophilicity on a glass substrate using the sessile drop method on a KRUSS instrument equipped with ADVANCE software (version 1.19.2.2630). A clean glass substrate was used for each measurement. A 1 mL plastic syringe fitted with a stainless-steel needle (0.7 mm diameter) was filled with the sample, and a droplet of approximately 3 pL was gently deposited onto the glass surface. The contact angle was recorded after 10 s of contact time. To account for variability, at least 100 measurements were collected. For samples that spread immediately (1-7 to 1-10), a stable droplet could not be maintained, and contact angles, therefore, could not be determined. This behavior was recorded by video and is reported as complete wetting. Surface tension measurements were carried out on the same KRUSS instrument equipped with ADVANCE software (version 1.19.2.2630) using the pendant drop method. Briefly, a 1 mL syringe fitted with a stainless-steel needle (1.2 mm diameter) was filled with the sample, and a droplet was formed at the needle tip. After equilibration, the surface tension was determined by fitting the droplet profile to the Young-Laplace equation in the instrument software.30'31To account for variability, each measurement was recorded at least 100 times.

[0318] Synthesis. The synthetic routes to the target compounds are outlined in Scheme 1, and all reactions were performed on a molar scale. Tail precursor 1 was prepared from ECH or glycidyl ethers through base-catalyzed epoxide ring opening with the corresponding alcohols.13, 14Tail precursor 1 was then converted either to glycidyl epoxide intermediate 2,32which was coupled with the diamine head group to afford ionizable lipid 3 (PIP),33or to tosyl 2',34which was subsequently transformed into glycerol-derived thiol S'.35The consistently good-to-excellent yields obtained at each step highlight the practicality of this modular glycerol-based synthetic approach.

[0319] In vitro transcription. mRNA derived from the Venezuelan Equine Encephalitis Virus (VEEV) encoding fLuc as the gene of interest was prepared using in vitro transcription. pDNA was transformed in Escherichia coh, cultured in 50 mL of LB with 100 ug / mL kanamycin (Sigma- Aldrich / Merck Life Science, Gillingham, U. K. ), and isolated using a Plasmid Plus Maxiprep kit (QIAGEN, MCR, U. K.). pDNA concentration and purity was measured using a NanoDrop One (Thermo Fisher Scientific, Loughborough, U. K.). mRNA was linearized using

[0320] Atorney Docket No. 10025-345W01 BtgZl for 2 hours at 60 °C, followed by fresh BtgZl addition and 60 °C incubation for 1 hour. Linearization was confirmed by flash gel electrophoresis (Lonza, Visp, Switzerland), with undigested plasmid control for comparison. Following restriction enzyme digestion, IV was conducted using HiScribe T7 High Yield RNA Synthesis Kit (New England Biolabs, Ipswich, MA, U. S. A.). The RNA was co-transcriptionally capped with CleanCap AG (mRNA) technology (Tebubio, Le Perray-en-Yvelines, France). The transcripts were purified by lithium chloride (Thermo Fisher Scientific, U. K.) precipitation, stored overnight at -20 °C, centrifuged at 14,000 rpm at 4 °C for 20 minutes, washed with 70% cold ethanol, centrifuged at 14,000 rpm at 4 °C for 5 minutes, and resuspended in nuclease-free water. mRNA concentration and purity were measured and stored under -80 °C.

[0321] Formulation manu facturing. A given ionizable lipid, DSPC, cholesterol and DMPE-PEG 2000 (Avanti Polar Lipids, U. S. A.) were used to formulate the LNPs. Each of the ionizable lipids, DMPE-PEG2000, DSPC, and cholesterol were dissolved in absolute ethanol. saRNA and mRNA were each prepared in 50 mM sodium acetate and 100 mM sodium chloride buffer (pH 5.5). The weight ratio of saRNA and mRNA to ionizable lipid was 0.013 and 0.022, respectively.

[0322] The formulations were manufactured using the NanoAssemblr Ignite (Precision NanoSystems, Vancouver, BC, Canada). The flow rate ratio oflipid to RNA was 1:3 and the total flow rate was 8 mL / min. The formulations were diluted in IX DPBS 5 times, then concentrated through a VivaSpin 6 filter tube (Sartorius, Gottingen, Germany ) of 10 kDa molecular weight cut-off at 4000 rpm, 18 °C to achieve the desired concentrations.

[0323] Dynamic light scattering and zeta potential measurements. A Zetasizer Nano ZS (Malvern Panalytical, Malvern, U. K.) was used to determine the Dh, PDI and zeta potential values of each formulation. The formulations were diluted in 850 pL of IX DPBS at a 1:100 dilution at 25 °C, transferred to DTS1070 cuvetes, and inserted into the Zetasizer Nano ZS instrument. The parameters applied include an absorbance of 0.010, dispersant viscosity of 0.8820 cP, refractive index of 1.330, and dielectric constant of 79.

[0324] Encapsulation efficiency measurements. Quant-iT RiboGreen assay (Thermo Fisher Scientific, U. K.) was used according to the manufacturer’s instructions to quantify the encapsulation efficiency and amount of saRNA and mRNA encapsulated in the LNPs.

[0325] Formulations were diluted in IX TE buffer to 6 pg / mL and mixed with IX IE buffer or 2% Triton X-100 at a 1:1 ratio in a black 96-well Costar plate (Thermo Fisher Scientific, U. K.). RNA standards were prepared according to the manufacturer’s instructions and pipetted into the 96-well Costai-plate. Formulations and standards were incubated at 37 °C for 10 minutes, and subsequently at 25 °C for 5 minutes. RiboGreen reagent was diluted in IX TE buffer at a 1:100Atorney Docket No. 10025-345W01 dilution, and 100 pL diluted RiboGreen reagent was added to each well. The plate was analyzed on the FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany) at excitation of 480 nm and emission of 52.0 nm. Based on the standard curve, the concentration of encapsulated RNA was calculated by subtracting the non-encapsulated RNA concentration from the total RNA concentration.

[0326] Cell culture and in vitro transfection efficacy measurements. HEK293T.17 and HeLa (ATCC, Manassas, VA, U. S. A.) cells were cultured in complete Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Fisher Scientific, U. K.). THP-1 cells (ATCC, U. S. A.) were cultured in complete Roswell Park Memorial Institute (RPMI) 1640 medium with 10% FBS, 1% L-glutamine and 1% pen-strep. Cells were plated in a 96-well plate 24 hours prior to transfection at a density of 5 xlO4cells per well for HEK293T.17 and HeLa cells; and 8x 104cells per well for THP-1 cells. Transfection of saRNA and mRNA encoding fLuc was performed using Lipofectamine MessengerMAX (Thermo Fisher Scientific, U. K.) according to the manufacturer’s instructions. At 24 hours post-transfection, half of the cell supernatants were discarded from each well and an equal volume of the ONE-Glo Luciferase (Promega, Chilworth, U. K.) was added, then placed in the dark. Cells were incubated with the luciferase reagent for 5 minutes, ensuring complete cell lysis, then pipetted up and down and transferred to a 96-well Costar plate. Luminescence was measured on the FLUOstar Omega microplate reader using gain 2500.

[0327] Results and discussion

[0328] Water content. The low residual water contents measured after drying indicate that the synthesized tail alcohols can be effectively dehydrated prior to physicochemical characterization. However, water content should not be interpreted as a direct descriptor of tail hydrophobicity alone, because it depends on the full molecular framework, including the glycerol-derived alcohol / ether core, hydrogen-bonding sites, sample handling, and drying efficiency.-’6'38Accordingly, in tliis work, low residual water content is used primarily to confirm sample suitability for subsequent property measurements rather than as an independent measure of hydrophobic tail character. All tails were dried over 3 A molecular sieves to reduce water content below' 0.1 't % H2O (i.e., <1000 ppm).

[0329] Solvent densities (p). To further examine how tail architecture influences molecular packing in this glycerol-derived series, density was used as a simple yet informative structure¬ property descriptor. In ionizable lipid systems, branching, unsaturation, and tail geometry are known to affect the effective tail cross-section, free volume, and hydrophobic organization, which, in turn, influence fluidity and phase behavior.19, 21The densities of all tails were

[0330] Atorney Docket No. 10025-345W01 measured over 293.15-343.15 K at 0.1 MPa. The results are shown in Figure 2. Linear fits for each neat compound gave R2values greater than 0.9999.

[0331] In the present series, the densities of 1-1 to 1-10 decrease nearly linearly with increasing temperature over 293.15-343.15 K, consistent with related glycerol- and serinol-derived liquids. At 293.15 K, the densities range from 0.88631 to 0.94160 g cm”3, with 1-4 exhibiting the lowest value and 1-5 the highest. The low density of 1-4 is consistent with the presence of two bulky 2-ethylhexyl tails, which increase free volume and reduce packing efficiency. In contrast, the higher densities of 1-5 and 1-2 suggest that unsaturated terpene- or allyl-containing tails can pack more compactly than highly branched 2-ethylhexyl-rich structures within this scaffold. The comparison between 1-2 and 1-3 further indicates that subtle changes in terpene-tail geometry and unsaturation can measurably affect packing efficiency. Among the mixed-tail compounds containing one 2-ethylhexyl group, 1-8 and 1-10 are denser than 1-9 at 293.15 K, suggesting that replacement of a saturated butoxy group with a shorter unsaturated substituent can increase packing density. Overall, density trends are governed primarily by tail -dependent steric volume and packing efficiency, with bulky branching lowering density and less sterically expanded unsaturated motifs favoring higher density.

[0332] Refractive index (no). Refractive index (RI) is a useful structure -property descriptor because it reflects molecular polarizability per unit volume and is sensitive to substituent-dependent packing. In lipid-related systems, RI has been used to probe molecular polarizability, orientational order, and surface mass density, while classical studies of fatty acid esters have shown that RI varies systematically with chain structure and degree of unsaturation.39'42

[0333] In the present series, the RI values at 298.15 K range from 1.4356 to 1.4841, with 1-2 exhibiting the highest value and 1-7 the lowest. The results are shown in Figure 3.

[0334] Tails containing unsaturated terpene-derived or allylic tails, particularly 1-2, 1-5, 1-3, and 1-6, show relatively high RI values of 1.4841, 1.4744, 1.4654, and 1.4647, respectively, indicating that tail unsaturation increases refractivity, likely because of enhanced n- electron polarizability. This trend is also evident in the comparison of 1-2 and 1-3, where 1-2 remains distinctly higher than 1-3 despite their closely related terpene -based frameworks. In contrast, the saturated tails 1-7 and 1-9 exhibit the lowest RI values,

[0335] 1.4356 and 1.4376, respectively. Tails 1-8 and 1-10 are both higher than 1-9, further suggesting that replacement of a saturated tail with a shorter unsaturated tail increases RI.

[0336] Overall, these results indicate that tail unsaturation is the primary factor increasing RI within this common glycerol-derived framework, whereas saturated and more sterically

[0337] Atorney Docket No. 10025-345W01 diffuse alkyi tails produce lower refractivity. Accordingly, RI may serve as a rapid screening parameter for subsequent tail design.

[0338] Dynamic viscosities (η). Viscosity is a useful structure -- property descriptor for evaluating tail mobility, intermolecular packing, and formulation processability. Although viscosity alone does not predict delivery efficiency, recent LNP studies show that ionizable lipid tail length, branching, and unsaturation strongly influence mRNA delivery performance, underscoring the value of tail-level physicochemical screening.19, 23, 43The viscosities of all tails were measured over 293.15-343.15 K. The results are shown in Figure 4. The temperature dependence was modeled using the Andrade equation, η = a· exp (b / T), which has previously been applied to related glycerol-derived systems.13, 14The fitted parameters yielded strong correlations (R2> 0.99), confirming the model’s suitability.

[0339] Consistent with related glycerol- and serinol-derived systems, the viscosities of tails 1-1 to 1-10 decrease continuously with increasing temperature over 293.15-343.15 K, reflecting reduced intermolecular cohesion and enhanced molecular mobility at elevated temperature. At 293.15 K, the viscosities range from 13.74 cP for 1-8 to 28.71 cP for 1-3, and decrease to 6.34- 9.27 cP at 343.15 K, indicating that all compounds remain relatively fluid across the measured range. The higher viscosities of 1-2 and 1-3 are attributed to their larger terpene-derived tails, which increase hydrophobic contact area and dispersion interactions. In contrast, the lower viscosities of 1-8, 1-9, and 1-10 suggest that asymmetry, branching, and shorter tail fragments disrupt efficient packing and reduce resistance to flow. Because lipid-tail architecture influences molecular packing, membrane fluidity, and endosomal escape, these viscosity trends provide useful early-stage guidance for selecting tails that balance hydrophobicity with formulation-relevant fluidity.19

[0340] Contact angle and surface tension. The contact angle (CA) and surface tension (SFT) data collectively confirm the surface-active character of the synthesized tail alcohols and provide insight into their relevance to lipid-tail design. In lipid systems, these parameters are not merely empirical wetting descriptors. Contact angle has been identified as an important variable governing the stable adsorption of lipid monolayers on solid surfaces, whereas low surface tension is closely associated with lipid-layer reorganization, including folding, squeeze-out, and multilayer formation at interfaces.44, 45Recent studies further show that tail unsaturation and tail architecture can strongly influence surface activity, self-assembly, membrane fluidity, and membrane fusion behavior, while ionizable lipid tail structure also plays a key role in pH- responsive membrane disruption and endosomal escape.46-48Accordingly, although the present measurements were performed on neat liquids rather than assembled lipid nanoparticles, CA andAtorney Docket No. 10025-345W01 SFT remain useful early-stage descriptors of tail -controlled amphiphilicity and interfacial behavior.

[0341] The CA and SFT results collectively confirm the surface-active character of the synthesized molecules (Figure 5a, Figure 5b). Relative to DI water under the present experimental conditions (12.93 ± 1.69°), tails 1-1 to 1-3 exhibited higher contact angles (1-1, 21.90 ± 2.09°; 1-2, 26.54 ± 0.46°; 1-3, 22.27 ± 1.16°), indicating reduced wetting on glass and modestly greater resistance to spreading. This behavior is consistent with the larger hydrophobic contribution from their alkyl or unsaturated tail structures. In contrast, 1-4 exhibited a lower contact angle (7.86 ± 0.88°), which should be interpreted as stronger spreading on the high- energy glass substrate rather than as direct evidence of greater molecular hydrophilicity. Tails 1-5 and 1-6 showed wetting behavior closer to that of DI water, suggesting that the balance between the polar glycerol -derived core and hydrophobic substituents governs droplet spreading.49For tails 1-7 to 1-10 (Figure 6a-Figure 6d), droplets spread immediately upon contact with glass, preventing measurement of a stable contact angle and indicating complete wetting.50This behavior likely reflects the combined influence of low liquid surface tension, strong substrate adhesion, and flexible / asymmetric tail structures that facilitate rapid interfacial adsorption. As a result, the balance between adhesive and cohesive forces shifts strongly toward spreading.31

[0342] Furthermore, all samples exhibited lower surface tensions (23.55-30.12 mN / m) than DI water (66.72 mN / m), consistent with efficient adsorption at the air-liquid interface. This reduction in surface tension arises from the amphiphilic character of the molecules, in which the polar head groups remain preferentially associated with the bulk liquid while the nonpolar tails orient toward the air interface, thereby reducing cohesive interactions within the liquid. The relatively narrow range of surface tension values indicates that, despite structural differences such as unsaturation and chain branching, all compounds adsorb effectively at the liquid-air interface.51, 52Taken together, these results suggest that tail modification in this series primarily tunes wetting behavior and interfacial packing, whereas the common glycerol-derived polar core preserves strong overall surface activity. This interpretation is consistent with recent lipid-tail studies showing that tail unsaturation and geometry modulate interfacial properties and self- assembly even when the overall amphiphilic framework is retained.

[0343] Miscibility. The miscibility results in Figure 7 show a consistent structure-property pattern across the glycerol-derived tail series. Tails 1-1 to 1-10 are immiscible with water but readily miscible with common organic solvents, consistent with previous observations for related glycerol-derived liquids.13, 16This behavior indicates that the appended hydrophobic tailsAtorney Docket No. 10025-345W01 suppress water compatibility, whereas the common glycerol-derived alcohol / ether framework retains sufficient polarity to support broad solvation in organic media. In the context of lipid-tail design, this organophilic but water-immiscible profile is relevant because tail structure governs hydrophobic-domain formation, molecular packing, and formulation behavior in ionizable lipids.19, 21Accordingly, miscibility provides a practical early-stage descriptor for evaluating whether the tail precursors possess an appropriate balance of hydrophobicity and processability for subsequent amphiphile synthesis.

[0344] Lipid nanoparticles for mRNA delivery. The ionizable lipids 3N-74-M, 1N-74-M, 3N-77-M, 3N-77-E, and PIP-77-E were used to formulate LNPs for mRNA delivery. Each of the ionizable lipids was combined with distearoylphosphatidylcholine (DSPC), cholesterol, and DMPE-PEG 2000 at 50:10:38.5:1.5 molar ratio, and the LNPs were assembled via microfluidics.

[0345] First dynamic light scattering and zeta potential measurements were performed to determine the hydrodynamic diameter (Dh) and polydispersity index (PDI) values of the LNPs, as well as LNP surface charge. This would provide preliminary insight into the influence of the distinct ionizable lipids on the physicochemical properties of the LNPs. It was found that for each ionizable lipid, the LNPs presented Dh values below 100 nm, and PDI values between 0.22 and 0.39 (Figure 8a). The LNPs exhibited zeta potential values ranging between -1.5 mV and - 4.4 mV, least negative for 3N-77-E LNPs and most negative for PIP-77 -E LNPs (Figure 8b). Overall, it was found that the LNP encapsulation efficiency of mRNA was above 85%, apart from the 3N-74-M LNP showing 75% encapsulation efficiency (Figure 8c).

[0346] Finally, the in vitro transfection efficiency of each of the LNP formulations, using firefly luciferase (fLuc) as a reporter protein, was evaluated. The formulations of fLuc-encoding mRNA were transfected into HEK293 cells to determine the influence of each ionizable lipid on mRNA- LNP transfection efficiency in vitro. Based on the luciferase expression, it was observed that the LNPs achieved different levels of delivery, and the transfection efficiency of each of the LNPs was superior to that of naked RNA (Figure 8d). In particular, the LNPs including 3N-77-E, 3N- 74-M and PIP-77-E showed the highest transfection efficiencies, with PIP-77 -E presenti ng transfection efficiency of approximately 103RLU. This highlights that each of the LNPs achieved intracellular’ mRNA delivery in vitro, and PIP-77-E offers the most effective capabilities. Notably, optimizing the component ratios of the LNPs and microfluidic manufacturing parameters could further improve the performance of the formulations.

[0347] Conclusions. This work establishes activated glycerol chemistry as a practical route from renewable small molecules to larger functional amphiphiles. A library of ten glycerol -derived tail alcohols was prepared on a common glycerol-di ether scaffold while systematically varyingAtorney Docket No. 10025-345W01 branching, unsaturation, chain length, and symmetry. This design enables direct comparison of hydrophobic-tail descriptors within a unified molecular framework rather than across unrelated lipid structures. The resulting physicochemical data show that tail architecture measurably influences packing, refractivity, fluidity, surface activity, wetting, and organic-solvent compatibility. In particular, bulky branched motifs reduce packing efficiency, unsaturated tails increase refractive index and alter interfacial behavior, and asymmetric structures can lower viscosity and promote wetting. Beyond tail screening, the platform is synthetically versatile: the same scaffold can be advanced to glycidyl-functionalized amphiphiles, ionizable lipids, or glycerol-derived thiols for subsequent thiol-ene chemistry. The synthesis of a representative ionizable lipid, PIP, provides an initial proof of concept that these renewable tail precursors can be translated into delivery-relevant architectures. Because the biological evaluation is currently limited to an initial representative structure, future studies should expand formulation and delivery screening across the full tail library to establish detailed structure-activity relationships. More broadly, this study positions glycerol -derived tails as modular building blocks for multifunctional molecular design, with potential applications extending beyond RNA delivery.

[0348] References

[0349] (1) Quispe, C. A. G. et al. Glycerol: Production, Consumption, Prices, Characterization and New Trends in Combustion. Renew. Sustainable Energy Rev. 2013, 27, 475-493.

[0350] (2) Tan, H. W. et al. Glycerol Production and Its Applications as a Raw Material: A Review. Renew. Sustainable Energy Rev. 2013, 27, 118-127.

[0351] (3) da Costa, A. A. F. et al. Glycerol and Microwave- Assisted Catalysis: Recent Progress in Batch and Flow Devices. Sustainable Energy Fuels 2023, 7, 1768-1792.

[0352] (4) Elsayed, M. et al. Sustainable Valorization of Waste Glycerol into Bioethanol and Biodiesel through Biocircular Approaches: A Review. Environ. Chem. Lett. 2024, 22, 609-634.

[0353] (5) Koranian, P. et al. Chemicals Production from Glycerol through Heterogeneous

[0354] Catalysis: A Review. Catalysts 2022, 12, 897.

[0355] (6) Wang, J. et al. Synthesis and Properties of 1,3 -Dimethoxy acetone: A Glycerol- Derived Solvent. Ind. Eng. Chem. Res. 2025, 64, 14744-14754.

[0356] (7) Qian, S. et al. Glycerol-Derived Solvents Containing Two or Three Distinct Functional Groups Enabled by Trifluoroethyl Glycidyl Ether. AIChE J. 2022, 68, e17533.

[0357] (8) Lingua, G. et al. Solvate Ionic Liquids Based on Branched Glymes Enabling High Performance Lithium Metal Batteries. J. Power Sources 2024, 624, 235535.

[0358] (9) Foster, S. E. et al. Acetalization of Symmetric Ketones with 1,2-Propanediol over Amorphous Solid Lewis Acids. Ind. Eng. Chem. Res. 2026, 65, 2071-2084.

[0359] Atorney Docket No. 10025-345W01

[0360] (10) Qian, S. et al. Synthesis and Properties of 1,2,3-Triethoxypropane: A Glycerol -Derived Green Solvent Candidate. Ind. Eng. Chem. Res. 2020, 59, 20190-20200.

[0361] (11) Qian, S. et al. Synthesis and Properties of Symmetric Glycerol-Derived 1,2,3-Triethers and 1,3-Diether-2-Ketones for CO2 Absorption. Chem. Eng. Sci. 2022, 248, 117150.

[0362] (12) Qian, S. et al. Properties of Symmetric 1,3-Diethers Based on Glycerol Skeletons for

[0363] CO2 Absorption. Fluid Phase Equilib. 2020, 521, 112718.

[0364] (13) Wang, J. et al. Synthesis and Properties of Novel Glycerol-Derived Liquids with Dual Functional Groups: Nonsymmetric (E / Z)-Isomeric Mixtures of 1,3-Diether-2-Alkenes. Chem. Eur. J. 2025, 31, e202401406.

[0365] (14) Wang, J. et al. Synthesis and Properties of Symmetric Glycerol-Derived (E / Z)-1,3-

[0366] Diether-2-Alkenes. Ind. Chem. Mater. 2026, 4, 131-141.

[0367] (15) Chatterjee, S. et al. Synthesis and Properties of 2-Halo-l,3-Diether-Propanes:

[0368] Diversifying the Range of Functionality in Glycerol-Derived Compounds. Ind. Eng. Chem. Res.

[0369] 2023, 62, 2959-2967.

[0370] (16) Wang, J. et al. Serinol as a Tunable and Sustainable Framework for High-Capacity,

[0371] Low- Viscosity, Water-Lean CO2 Capture and Switchable Solvents. Mol. Syst. Des. Eng. 2025, 10, 1028-1033.

[0372] (17) Wang, J. et al. Switchable Single-Component Water-Lean Serinol-Based CO2.

[0373] Capture Solvents Achieve High Capacity and Maintain Low Viscosity. Chem. Eng. Sci. 2026, 329, 123791.

[0374] (18) Zhang, Y. et al. Principles of Lipid Nanoparticle Design for mRNA Delivery.

[0375] BMEMat 2025, 3, e12116.

[0376] (19) Han, X. et al. An Ionizable Lipid Toolbox for RNA Delivery. Nat. Commun. 2021, 12, 7233.

[0377] (20) Hou, X. et al. Lipid Nanoparticles for mRNA Delivery. Nat. Rev. Mater. 2021, 6,

[0378] 1078-1094.

[0379] (21) Eygeris, Y. et al. Chemistry of Lipid Nanoparticles for RNA Delivery. Acc. Chem. Res. 2022, 55, 2-12.

[0380] (22) Yan, Y. et al. Branched Hydrophobic Tails in Lipid Nanoparticles Enhance mRNA Delivery for Cancer Immunotherapy. Biomaterials 2023, 301, 122279.

[0381] (23) Mrksich, K. et al. Influence of Ionizable Lipid Tail Length on Lipid Nanoparticle Delivery of mRNA of Varying Length. J. Biomed. Mater. Res., Part A 2024, 112, 1494-1505.

[0382] (24) Liu, C. et al. Multiple-Tail Ionizable Lipids Improve In Vivo mRNA Delivery Efficiency with Biosafety. Int. J. Pharm. 2024, 667, 124868.

[0383] Atorney Docket No. 10025-345W01

[0384] (25) Hashiba, K. et al. Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of mRNA. Small Sci. 2023, 3, 2200071.

[0385] (26) Huang, K. et al. Nebulized lipid nanoparticles based on degradable ionizable glycerolipid for potent pulmonary mRNA delivery. ACS nano 2025, 19 (1), 1128-1139.

[0386] (27) Pour, Z. S. et al. 1,3-Diether-2-Methacrylates with Glycerol Skeletons: Tunable

[0387] Resins for Stereolithography 3D Printing. Polym. Chem. 2025, 16, 2840-2850.

[0388] (28) Pour, Z. S. et al. Toward sustainable SLA 3D printing: glycerol-based 1, 3-diether-2- methacrylates with solvent capability for in situ polymer blend formation. RSC Applied Polymers 2026, Advance article. DOI: https: / / doi.org / 10.1039 / D6LP00005C.

[0389] (29) Qian, S. et al. Experimental and Computational Study of the Properties of Imidazole

[0390] Compounds with Branched and Cycloalkyl Substituents. Liquids 2022, 2, 14-25.

[0391] (30) Berry, J. D. et al. Measurement of Surface and Interfacial Tension Using Pendant Drop Tensiometry. J. Colloid Interface Sci. 2015, 454, 226-237.

[0392] (31) Rosen, M. J.; Kunjappu, J. T. Surfactants and Interfacial Phenomena, 4th ed.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012. https: / / doi.org / 10.1002 / 9781118228920.

[0393] (32) Frey, H. et al. Immunologically Inactive Polyethylene glycol) Polymer Derivatives and Bioconjugates Thereof for Use as Alternative in PEGylated Therapeutics, Processes for Their Preparation and Their Use. WO2024256475A1, Dec 19, 2024.

[0394] (33) Love, K. T. et al. Lipid-like Materials for Low-Dose, In Vivo Gene Silencing. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 1864-1869.

[0395] (34) Mohy El Dine, T. et al. Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as Pseudomonas aeruginosa Antibiofilm Agents. J. Med. Chem. 2021, 64, 14728-14744.

[0396] (35) Atilla, D. et al. Highly Soluble Ni(II) vic-Dioxime Complexes Containing Branched Thioether with Alkyl Chains of Different Lengths: Synthesis and Characterization. J. Coord.

[0397] Chem. 2009, 62, 3050-3059.

[0398] (36) Pastre, A. et al. Coarse-Grained Simulations of RNA-Loaded Lipid Nanoparticles: Implications on RNA Stability and Antigenic Protein Expression in mRNA Vaccines. J. Phys. Chem. B 2025, 129, 9643-9657.

[0399] (37) Zwolsman, R. et al. Engineering Lipid Nanoparticles for mRNA Immunotherapy.

[0400] Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2025, 17, e70007.

[0401] (38) Jiao, X. et al. Insights into the Formulation of Lipid Nanoparticles for the Optimization of mRNA Therapeutics. Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2024, 16, e1992.

[0402] Atorney Docket No. 10025-345W01

[0403] (39) Hammond, E. G.; Lundberg, W. O. Molar Refraction, Molar Volume, and Refractive Index of Fatty Acid Esters and Related Compounds in the Liquid State. J. Am. Oil Chem. Soc.

[0404] 1954, 31, 427-432.

[0405] (40) Gouw, T. H.; Vlugter, J. C. Physical Properties of Fatty Acid Methyl Esters. II. Refractive Index and Molar Refraction. J. Am. Oil Chem. Soc. 1964, 41, 426-429.

[0406] (41) Salamon, Z.; Tollin, G. Optical Anisotropy in Lipid Bilayer Membranes: Coupled Plasmon-Waveguide Resonance Measurements of Molecular Orientation, Polarizability, and Shape. Biophys. J. 2001, 80, 1557-1567.

[0407] (42) Parkkila, P. et al. Biophysical Characterization of Supported Lipid Bilayers Using Parallel Dual- Wavelength Surface Plasmon Resonance and Quartz Crystal Microbalance

[0408] Measurements. Langmuir 2018, 34, 8081-8091.

[0409] (43) Lee, S. M. et al. A Systematic Study of Unsaturation in Lipid Nanoparticles Leads to Improved mRNA Transfection In Vivo. Angew. Chem. 2021, 133, 5912-5917.

[0410] (44) Sako, M. et al. Conditions for the Stable Adsorption of Lipid Monolayers to Solid Surfaces. PNAS Nexus 2023, 2, pgad190.

[0411] (45) Bykov, A. G. et al. Structural Changes in Layers of Lipid Mixtures at Low Surface Tensions. Chem. Phys. Lipids 2024, 258, 105365.

[0412] (46) Sekhar, K. P. C. et al. Tail-Group Unsaturation Tailors the Surface and Self-Assembly Behavior of C18-Fatty-Acid-Based Glycolipids. J. Mol. Liq. 2022, 351, 118585.

[0413] (47) Wei, Y. et al. A Cationic Lipid with Advanced Membrane Fusion Performance for pDNA and mRNA Delivery. J. Mater. Chem. B 2023, 11, 2095-2107.

[0414] (48) Lu, Z.-R.; Sun, D. Mechanism of pH-Sensitive Amphiphilic Endosomal Escape of Ionizable Lipid Nanoparticles for Cytosolic Nucleic Acid Delivery. Pharm. Res. 2025, 42, 1065- 1077.

[0415] (49) Good, R. J. Contact Angle, Wetting, and Adhesion: A Critical Review. J. Adhes. Sci.

[0416] Technol. 1992, 6, 1269-1302.

[0417] (50) Wang, X. et al. Wetting Behavior of Low Surface Tension Liquids on Surface with Re-Entrant Topological Features. Int. J. Heat Mass Transfer 2024, 229, 125699.

[0418] (51) Rekvig, L. et al. Effect of Surfactant Structure on Interfacial Properties. Europhys. Lett. 2003, 63, 902-907.

[0419] (52) Rosen, M. J. The Relationship of Structure to Properties in Surfactants. J. Am. Oil Chem. Soc. 1972, 49, 293-297.

[0420] Atorney Docket No. 10025-345W01

[0421] The compositions and methods of the appended claims are not limited in scope by the specific compositions and methods described herein, which are intended as illustrations of a few aspects of the claims and any compositions and methods that are functionally equivalent are intended to fall within the scope of the claims. Various modifications of the compositions and methods in addition to those shown and described herein are intended to fall within the scope of the appended claims. Further, while only certain representative compositions and method steps disclosed herein are specifically described, other combinations of the compositions and method steps also are intended to fall within the scope of the appended claims, even if not specifically recited. Thus, a combination of steps, elements, components, or constituents may be explicitly mentioned herein or less, however, other combinations of steps, elements, components, and constituents are included, even though not explicitly stated. The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of’ and “consisting of’ can be used in place of “comprising” and “including” to provide for more specific embodiments of the invention and are also disclosed. Other than in the examples, or where otherwise noted, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood at the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, to be construed in light of the number of significant digits and ordinary rounding approaches.

Claims

Atorney Docket No. 10025-345W01CLAIMSWhat is claimed is:

1. A compound having the formula:or pharmaceutically acceptable salt thereof, wherein;is a single bond or double bond;Zlais null, ()C(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Zlais a single bond when Zlais not null;Zlbis null, Cb-salkylene, or C2-salkyleneNR“lC2-8alkylene, wherein Rnlis H or Ci- 4alkyl;R1is a group having the formula:whereinR2is Ci-4alkyl or a group having the formula:whereinZ2ais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Z2ais a single bond when Z2ais not null;Z2bis null, C2-8alkylene, or C2-8alkyleneNRn2C2-8alkylene, wherein Rn2is H or C1-4alkyl;R3is Ci-4alkyl, absent, or a group having the formula:whereinZ3ais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that — connected to Z3ais a single bond when Z3ais not null;Z3bis null, C2-8alkylene, or C2-8alkyleneNRn3C2-8alkylene, wherein Rn3is H or C1-4alkyl;Attorney Docket No. 10025-345W01R‘ is Ci-4alkyl or a group having the formula:Ztais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Ztais a single bond when Ztais not null;Ztbis null, C2-8alkylene, or C2-8alkyleneNR”C2-8alkylene, wherein Rntis H or Ci- ralkyl;Y1is null, C2-8alkylene, or C2-8alkyleneNRy1C2-8alkylene, wherein Ry1is H or C1-4alkyl;or when Zlaand Zlbare null, and is a double bond, then R‘ can also be absent;R4is Ci-4alkyl or a group having the formula:whereinZ4ais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Z4ais a single bond when Z4ais not null;Z4bis null, C2-8alkylene, or C2-8alkyleneNRn4C2-8alkylene, wherein Rn4is H or C1-4alkyl;Y4is C2-salkylene or C2-8alkyieneNRy4C2-8alkylene, wherein Ry4is H or Ci-4alkyl;R4ais Ci-4alkyl or a group having the formula:Z4aais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Z4aais a single bond when Z4aais not null;Z4bais null, C2-8alkylene, or C2-8alkyleneNR4baC2-8alkylene, wherein R4bais H or C1-4alkyl;R4bis C1-4alkyl or a group having the formula:Atorney Docket No. 10025-345W01Z4abis null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Z4abis a single bond when Z4abis not null;Z4bbis null, C2-salkylene, or C2-salkyleneNR4bbC2-8alkylene, wherein R4bbis H or Ci-R4tis Ci^alkyl or absent;R5is Ci^alkyl or a group having the formula:whereinZ5ais null, provided that —connected to Z5ais a single bond when Z3ais not null;Z5bis null, C2-salkylene, or C28alkyleneNR5bC28alkylene, wherein Rsbis H or Ci-4alkyl;Y5is C2-8alkylene or C2-8alkyleneNRySC2-8alkylene, wherein Ry5is H or Ci^alkyl;R5ais Ci^alkyl or a group having the formula:Z5aais null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that connected to Z5aais a single bond when Z5aais not null;Z5bais null, C2-8alkylene, or C2-8alkyIeneNR’baC2-8alkylene, wherein R5bais H or Ci-R5bis Ci^alkyl or a group having the formula:Z5abis null, OC(=O), OC(=O)NH, NHC(=O), or NHC(=O)NH, provided that ™ connected to Z5abis a single bond when Z5abis not null;Z5bbis null, C -8alkylene, or C2-8alkyleneNR5bbC?.-8alkylene, wherein R5bbis H or Ci-R5tis Ci^alkyl or absent;wherein when any two or more of R2, R3, and Rlare Ci^alkyl, said R2, R3, and R* may together with the nitrogen to which they are attached form a C2-i2heterocyclic ring;Atorney Docket No. 10025-345W01 wherein when any two or more of R4, R5, and Rsare Cwalkyl, said R4, R5, and Rsmay together with the nitrogen to which they are attached form a ( Z 2- 12heterocycl ic ring; andwherein when any two or more of R4a, R4b, and R4tare Ci-4alkyl, said R4a, R4b, and R4tmay together with the nitrogen to which they are attached form a C > heterocyclic ring;wherein when any two or more of R5a, R5b, and R5tare Ci-4alkyl, said R5a, R3b, and R5tmay together with the nitrogen to which they are attached form a C2- heterocyclic ring; andLipid is in each case independently a Ceooalkyl group2. The compound of claim 1, wherein lipid is in each case independently a Co-22alkyl group, Ce- alkyl group, Ce-ualkyl group, C6-i2.alkyl group, or Cg-ioalkyl group.

3. The compound of claim 1, wherein one or more of the lipid groups comprises linear Cs- soalkyl group, Ce-22alkyl group, Ce-isalkyl group, Cg-i4alkyl group, Cg- alkyl group, or Cg-ioalkyl group.

4. The compound of claim 1, wherein each of the lipid groups comprises a linear Ce soalkyl group, C6-22alkyl group, Ce isalkyl group, Ce-ualkyl group, Cg-nalkyl group, or Cg-ioalkyl group.

5. The compound of claim 1, wherein one or more of the lipid groups comprises branched Cg-joalkyl group, Ce-22alkyl group, Ce-isalkyl group, Ce-nalkyl group, Cg-nalkyl group, or (>.. loalkyl group.

6. The compound of claim 1, wherein each of the lipid groups comprises a branched C - soalkyl group, Ce-22alkyl group, Ce-isalkyl group, Cg-i4alkyl group, Cg- alkyl group, or Cg-ioalkyl group.

7. The compound of claim 1, wherein the compound comprises at least one lipid group that is a saturated C6-3oalkyl group, C6-22alkyl group, Cg-isalkyl group, Ce-rtalkyl group, Ce-nalkyl group, or Ce-toalkyl group, and at least one lipid group that is a branched C6-3oalkyl group, G,.22alky 1 group, Ce-isalkyl group, Ce-walkyl group, Cg-nalkyl group, or Cg-ioalkyl group.

8. The compound of claim 1, wherein one or more of the lipid groups comprises saturated Ce soalkyl group, C6-22alkyl group, Cg-isalkyl group, Cg-ualkyl group, C6 i2alkyl group, or Cg walkyl group.Atorney Docket No. 10025-345W019. The compound of claim 1, wherein each of the lipid groups comprises an unsaturated Cc,-3oalkyl group, Ce-22alkyl group, Ce-isalkyl group, Ce-ualkyl group, C6-i2alkyl group, or Cs-ioalkyl group.

10. The compound of claim 1, wherein one or more of the lipid groups comprises branched Ce-soalkyl group, Ce-22alkyl group, Ce-isalkyl group, Ce-ualkyl group, Ce-nalkyl group, or Cc,-loalkyl group.

11. The compound of claim 1, wherein each of the lipid groups comprises an unsaturated O- soalkyl group, Ce-22alkyl group, Ce-isalkyl group, Cg-i4alkyl group, Ce- alkyl group, or Ce-toalkyl group.

12. The compound of claim 1, wherein the compound comprises at least one lipid group that is a saturated C'6-3oaikyl group, Cenalkyl group, Ce-isalkyi group, Ce-rtalkyl group, Ce-nalkyl group, or Ce-ioalkyl group, and at least one lipid group that is an unsaturated Ce-soaikyl group, Ce-22alkyl group, Ce-isalkyl group, Ce-nalkyl group, Ce-nalkyl group, or Ce ioalkyl group.

13. The compound of claim 1, wherein at least one of the lipid groups is derived from a fatty acid, for example crotonic acid, lauric acid, myristic acid, palmitic acid, stearic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, vaccenic acid, gadoleic acid, eicosenoic acid, erucic acid, linoleic acid, eicosadienoic acid, docosadienoic acid, linolenic acid, pinolenic acid, eleostearic acid, dihomo-y-linolenic acid, eicosatrienoic acid, tetra-unsaturated fatty acids, stearidonic acid, arachidonic acid, eicosatetraenoic acid, adrenic acid, bosseopentaenoic acid, eicosapentaenoic acid, ozubondo acid, sardine acid, tetracosanolpentaenoic acid, docosahexaenoic acid, herring acid, petroselinic acid, paullinic acid, gondoic acid, erucic acid, brassidic acid, nervonic acid, arachidonic acid, or a combination thereof.

14. The compound of claim 1, wherein each of the lipid groups is derived from a fatty acid, for example crotonic acid, lauric acid, myristic acid, palmitic acid, stearic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, vaccenic acid, gadoleic acid, eicosenoic acid, erucic acid, linoleic acid, eicosadienoic acid, docosadienoic acid, linolenic acid, pinolenic acid, eleostearic acid, dihomo-y-linolenic acid, eicosatrienoic acid, tetra-unsaturated fatty acids, stearidonic acid, arachidonic acid, eicosatetraenoic acid, adrenic acid, bosseopentaenoic acid, eicosapentaenoic acid, ozubondo acid, sardine acid, tetracosanolpentaenoic acid,Attorney Docket No. 10025-345W01 docosahexaenoic acid, herring acid, petroselinic acid, pauliinic acid, gondoic acid, erucic acid, brassidic acid, nervonic acid, arachidonic acid, or a combination thereof.

15. The compound of any of claims 1-14, wherein Zlaand Zlbare null, i.e., a compound having the formula:

16. The compound of any of claims 1-14, wherein Zlaand Z]bare null, is a single bond and each of R2, R3, and REare Ci 4alkyl, i.e., a compound of formula:

17. The compound of any of claims 1-14, wherein Ziaand Zlbare null, and is a double bond, and R3and R4are absent, i.e., a compound of formula:the tautomer thereof, i.e.,O— LipidLipid— O-~x— NH / N,HLipid— O R Lipid— O R; or a combination thereof.

18. The compound of any of claims 1-14, wherein Zlais O(C=O), Zlbis CTsalkylene, R“, Rfare Ci-4alkyl, and R3is absent or Ci-4alkyl, i.e., a compound having the formula:

19. The compound of any of claims 1-14, wherein Ziais O(C=O), Zlbis Cz-salkylene, R2is a group having the formula:Z2ais OC(=O);Z2bis C2-salkylene;Attorney Docket No. 10025-345W01R‘ is Ci-4alkyl;R3is absent, i.e., a compound having the formula:

20. The compound of any of claims 1-14, wherein Zlais O(C=O), Zlbis C2-salkylene, R2is a group having the formula:Z2ais OC(=O);Z2bis C2-salkylene;R3is absent;R* is a group having the formula:Ztais OC(=O); andZtbis Cz-aalkyiene; i.e., a compound having the formula:

21. The compound of any of claims 1-14, wherein Zlais O(C=O), Zlbis C2-8alkylene, R2is a group having the formula:Z2ais OC(=O);Z2bis C salkylene;R3is absent;Atorney Docket No. 10025-345W01R‘ is a group having the formula:R4L_YI-N— RSrR5Rsis Ci-4alkyl; i.e., a compound having the formula:

22. The compound of any of claims 1-14, wherein Zlais O(C=O), Zlbis Cz-salkylene, R2is a group having the formula:Z2ais OC(=O);Z2bis C2^alkylene;R3is absent;R is a group having the formula:R4HY1-N-RSR5Y1is C2-8alkylene;R4is a group having the formula:whereinY4is C2-8alkylene;R4ais a group having the formula:Atorney Docket No. 10025-345W01Z4aais OC(=O),Z4bais C2-8alkylene;R4bis a group having the formula:Z4abis OC(=O);Z4bbCi-salkylene;R4tis absent;R5is a group having the formula:whereinY5is C 2 -salkylene;R'!is a group having the formula:Z5aais OC(=O);Z5bais C2-salkylene;R5bis a group having the formula:Z5abis OC(=O);Z5bbis Cz-salkyiene; andR5tis absent: i.e. a compound having the formula:Atorney Docket No. 10025-345W0123. The compound of a preceding claim, wherein each of the lipid-containing nioieties has the formula:LipidLipidwherein Lapid 1 and Lipid 2 are not the same.

24. The compound of claims 23, wherein Lipid 1 is linear Cg-soalkyl group, C^alkyl group, Ce-isalkyl group, Cg-ualkyl group, Cg-nalkyl group, or Cg-ioalkyl group and Lipid 2 is a branched Cg-soalkyl group, Cg-22alkyl group, Cg-isalkyl group, Cg-nalkyl group, Cg-nalkyl group, or (>.. loalkyl group.

25. The compound of claims 23, wherein Lipid 1 is a saturated Cg-soalkyl group, C.-..-.-alkyl group, Cg-isalkyl group, Cg-ualkyl group, Cg-nalkyl group, or Ce-ioalkyl group, and Lipid 2 is an unsaturated Cg-soalkyl group, Cg-^alkyl group, Cg isalkyl group, Cg-ualkyl group, Cg-nalkyl group, or Ce-ioalkyl group.

26. The compound of claims 23, wherein Lipid 1 is a saturated Cg-soalkyl group, Cg..-.-alkyl group, Cg-isalkyl group, Cg-ualkyl group, Cg-nalkyl group, or Cg-ioalkyl group, and Lapid 2 is an unsaturated Cg-soalkyl group, C -22alkyl group, Cg-isalkyl group, Cg-ualkyl group, Cg-nalkyl group, or C -ioalkyl group.

27. The compound of claims 23, wherein Lipid 1 is a saturated Cg-soalkyl group, Cg-22alkyl group, Cg-isalkyl group, Cg-i4alkyl group, Cg-nalkyl group, or C -ioalkyl group, and Lipid 2 is an unsaturated Cg-soalkyl group, Cg-22alkyl group, Cg-isalkyl group, Cg-ualkyl group, Cg-nalkyl group, or C -ioalkyl group having one, two, three, four, or five carbon-carbon double bonds.

28. The compound of claims 23, wherein Lapid 1 is a saturated Cg-soalkyl group, Cg-22alkyl group, Cg-isalkyl group, Cg-i4alkyl group, Cg-isalkyl group, or Cg-ioalkyl group, and Lipid 2 is anAttorney Docket No. 10025-345W01 unsaturated Ce-soalkyl group, ( '-alky group, Ce-isalkyl group, Ce-ualkyl group, Ce-nalkyl group, or Ce-ioalkyl group having one, two, or three carbon-carbon double bonds.

29. The compound of claims 23, wherein Lipid 1 is a saturated C6-3oalkyl group, C^alkyl group, Ce-isalkyl group, Ce-ualkyl group, C6-i2alkyl group, or Ce-ioalkyl group, and Lipid 2 is an unsaturated Ce-3oalkyl group, C.-.??alkyi group, Ce-isalkyl group, Ce-ualkyl group, Ce-nalkyl group, or Ce-ioalkyl group having one, two, or three carbon-carbon double bonds in the cis configuration.

30. The compound of claims 23, wherein both Lipid 1 and Lipid 2 are unsaturated Ce-soalkyl groups, Ce-22alkyl groups, Ce-isalkyl groups, Ce-nalkyl groups, Ce-i2alkyl groups, or Ce-ioalkyl groups. In some implementations both Lipid 1 and Lipid 2 are unsaturated Ce-3oalkyl groups, Ce-22alkyl groups, Ce-isalkyl groups, Ce-ualkyl groups,!?al kyl groups, or Ce-ioalkyl groups having one, two, three, four, or five carbon-carbon double bonds.

31. The compound of claims 23, wherein both Lipid 1 and Lipid 2 are unsaturated Ceooalkyl groups, Ce-22alkyi groups, Ce-isalkyl groups, Ce-nalkyl groups, Ce- alkyl groups, or Ce-ioalkyl groups having one, two, or three carbon-carbon double bonds.

32. The compound of claims 23, wherein both Lipid 1 and Lipid 2 are unsaturated Ce-soalkyl groups, Ce-22alkyl groups, Ce-isalkyl groups, Ce-ualkyl groups, Ce-walkyl groups, or Ce-ioalkyl groups having one, two, or three carbon-carbon double bonds in the cis configuration.

33. A method of preparing the compound of any of claims 1-32, comprising reacting ammonia, primary amine, or secondary amine compound with a compound having the formula:wherein Ryis C?.-8alkyiene, and X is a suitable leaving group, for example Cl, Br, I, OMs, or OTs.

34. The method of a preceding claim, wherein the ammonia, primary amine, or secondary amine compound has the formula:Rais H, Chalky!, optionally substituted by NH2, NHCi-4alkyl, or N(Ct-4alkyl):Attorney Docket No. 10025-345W01 Rbis H, Ci-4alkyl, optionally substituted by NH2, NHCi-4alkyl, or NtCi^alkyl)?.;Rcis H, Ci-4alkyl, optionally substituted by NH2, NHCi-4alkyl, or N(Ci 4alkyl)2.

35. The method of a preceding claim, wherein Rais substituted by NH2, NHCi-4alkyl, or N(Ci-4alkyl)2, and Rais a linear C2-4alkyl, with the amine substitution occurring on the terminal carbon of the chain.

36. The method of a preceding claim, wherein Rbis substituted by NH2, NHC alkyl, or N(Ci-4alkyl)2, and Rbis a linear ( ' ■ ilky i. with the amine substitution occurring on the terminal carbon of the chain.

37. The method of a preceding claim, wherein Rcis substituted by NH2, NHCi-4alkyl, or N(Ci 4alkyl)2, and Rcis a linear C2 aalkyl, with the amine substitution occurring on the terminal carbon of the chain.

38. The method of a preceding claim, wherein:Rais H and Rband Rcare each Ct-4alkyl;Rais Ci-4alkyl and Rband Rcare each Chalky! substituted by NH2, NHCi^alkyl, orN(Ci 4alkyl)2, preferably Nib; orRaand RbCi-4alkyl and Rcis Ci-4alkyl substituted by NH2, NHCi-4alkyl, or N(Ci-4alkyl)2, preferably NH2.

39. The method of a preceding claim, wherein the amine compound is selected from:

40. A compound prepared by the method of a preceding claim.

41. A pharmaceutical composition comprising the compound of any preceding claim and an active agent.

42. The composition of claim 41, wherein the active agent comprises a therapeutic agent, a diagnostic agent, a cell, or immunomodulatory agent.Atorney Docket No. 10025-345W0143. The composition of claim 41, wherein the immunomodulatory agent is a vaccine.

44. The composition of claim 43, wherein the vaccine comprises a protein, nucleic acid, or combination thereof.

45. The composition of claim 43, wherein the vaccine comprises a nucleic acid.

46. The composition of claim 45, wherein the nucleic acid comprises single-stranded DNA, double stranded DNA, encapsulated DNA, complexed DNA, naked RNA, messenger RNA (mRNA), encapsulated RNA, tRNA, short interfering RNA (siRNA), antisense RNA (asRNA), amplify mRNA (saRNA), double stranded RNA (dsRNA), micro-RNA (miRNA), self-guide RNA (gRNA), cRNA, or a combination thereof.

47. The composition of claim 46, wherein the nucleic acid comprises mRNA.

48. The composition of claim 47, wherein the mRNA comprises a modified RNA.

49. A lipid nanoparticle comprising the compound of a preceding claim, an active agent, and one or more additional lipids or sterols.

50. The lipid nanoparticle of a preceding claim, wherein the lipid nanoparticle comprises one or more cationic lipids.

1. The lipid nanoparticle of a preceding claim, wherein the lipid nanoparticle comprises one or more ionizable lipids.

52. The lipid nanoparticle of a preceding claim, wherein the lipid nanoparticle comprises one or more non-cationic lipids.

53. The lipid nanoparticle of a preceding claim, wherein the lipid nanoparticle comprises one or more non-ionizable lipids.

54. The lipid nanoparticle of a preceding claim, wherein the lipid nanoparticle comprises one or more PEG-modified lipids.

55. The lipid nanoparticle of a preceding claim, wherein the lipid nanoparticle comprises ionizable lipid and / or cationic lipid, phospholipid / helper lipid, cholesterol, PEG-modified lipid.

56. The lipid nanoparticle of a preceding claim, wherein the lipid nanoparticle comprises a helper lipid fraction: preferably wherein the helper lipid fraction comprises a helper lipidAtorney Docket No. 10025-345W01 selected from the group consisting of distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylethanolamine (DOPE), dipalmitoylphosphatidylcholine (DOPC), phosphatidylcholine (PC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2- dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), and mixtures thereof.

57. The lipid nanoparticle of a preceding claim, wherein the lipid nanoparticle comprises a cleavable lipid.

58. A composition comprising the lipid nanoparticle of a preceding claim.

59. The composition of a preceding claim, wherein said composition is lyophilized or a reconstituted lyophilized composition.

60. The composition of claim 59, wherein the composition is lyophilized.

61. A method of preventing infection by an infectious vector in a subject, comprising administering to the subject a composition comprising a vaccine and the compound of a preceding claim.

62. A method of selectively delivering an active agent to a cell in a subject in need thereof, comprising administering to the subject a composition comprising the agent and a compound of a preceding claim.

63. The method of a preceding claim, wherein the cell comprises hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, lung cells, hone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes, or tumor cells.